Changzhou Qianhong Biopharma News

Qianhong Pharmaceutical (002550): Heparin API gross margin rebounded, boosting performance and looking forward to innovation, transformation and implementation

Jul 6 00:00

Qianhong Pharmaceutical (002550): 2023 performance under pressure 2024Q1 gross margin increased significantly

Jun 10 14:06

Qianhong Pharmaceutical (002550) Company Brief Review Report: Heparin APIs are expected to rebound, and innovative research and development are progressing smoothly

Apr 29 00:00

Comments on the 2023 Annual Report and 2024 Quarterly Report of Qianhong Pharmaceutical (002550): Cash flow conditions have greatly improved, innovation and transformation can be expected in the future

Apr 26 20:31

Qianhong Pharmaceutical (002550): Deepening the innovative layout of the entire heparin industry chain can be expected in the future

Mar 5 00:00

Qianhong Pharmaceutical (002550): Deepening the heparin industry chain with excellent results in innovative research and development

Jan 31 12:02

Qianhong Pharmaceutical (002550): Stock buybacks show confidence in development, heparin's upward cycle is expected to begin

Jan 4 15:32

Qianhong Pharmaceutical (002550): Continued improvement in the heparin supply and demand pattern is expected to start a new cycle of rapid growth

Dec 19, 2023 14:16

Qianhong Pharmaceutical (002550): Leading heparin API companies layout high-quality upstream resources can be expected in the future

Dec 4, 2023 07:42

Qianhong Pharmaceutical (002550): Heparin cycle, demolition compensation, exchange profit and loss affect performance layout Qianmu builds core competitiveness

光大證券Jul 25, 2023 07:17

Qianhong Pharmaceutical (002550) Annual Report Review: 2019 Main Business Performance Was Brilliant, 2020 Q1 Was Clearly Impacted by the COVID-19 Pandemic

平安證券Apr 27, 2020 00:00

Qianhong Pharmaceutical (002550) Case Review: The company's main business performance is outstanding and the innovative drug pipeline continues to be rich

平安證券Mar 1, 2020 00:00

Qianhong Pharmaceutical (002550): The ZHB202 clinical trial was approved and development has entered the harvest period

東北證券Nov 12, 2019 00:00

Qianhong Pharmaceutical (002550) Case Review: Innovative drug research and development has welcomed another significant progress since 2019 and has entered a period of harvesting results

平安證券Nov 7, 2019 00:00

Qianhong Pharmaceutical (002550): Employees have consistent shareholding interests and are optimistic about long-term development

國聯證券Aug 30, 2019 00:00

Qianhong Pharmaceutical (002550): Continued release of new products and performance is expected to accelerate

國聯證券Aug 26, 2019 00:00

Comments on Qianhong Pharmaceutical (002550) semi-annual report: half-yearly report results gratifying company's steady expansion

天風證券Aug 26, 2019 00:00

Qianhong Pharmaceutical (002550): steady income growth performance is expected to improve

國聯證券Apr 23, 2019 00:00

Qianhong Pharmaceutical (002550): the performance is basically in line with the expected high-speed release of low molecular weight heparin preparation.

平安證券Apr 23, 2019 00:00

Qianhong Pharmaceutical (002550): Natroheparin was successfully approved to enhance comprehensive competitiveness

國聯證券Mar 13, 2019 00:00